Cargando…

The role of tau in the pathological process and clinical expression of Huntington’s disease

Huntington’s disease is a neurodegenerative disorder caused by an abnormal CAG repeat expansion within exon 1 of the huntingtin gene HTT. While several genetic modifiers, distinct from the Huntington’s disease locus itself, have been identified as being linked to the clinical expression and progress...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vuono, Romina, Winder-Rhodes, Sophie, de Silva, Rohan, Cisbani, Giulia, Drouin-Ouellet, Janelle, Spillantini, Maria G., Cicchetti, Francesca, Barker, Roger A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4572485/ https://www.ncbi.nlm.nih.gov/pubmed/25953777 http://dx.doi.org/10.1093/brain/awv107

Ejemplares similares

GSK-3β-induced Tau pathology drives hippocampal neuronal cell death in Huntington's disease: involvement of astrocyte–neuron interactions
por: L'Episcopo, F, et al.
Publicado: (2016)

Untangling the Role of Tau in Huntington’s Disease Pathology
por: Salem, Shireen, et al.
Publicado: (2023)

Association Between Toll‐Like Receptor 4 (TLR4) and Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) Genetic Variants and Clinical Progression of Huntington's Disease
por: Vuono, Romina, et al.
Publicado: (2019)

Passive immunization against phosphorylated tau improves features of Huntington's disease pathology
por: Alpaugh, Melanie, et al.
Publicado: (2022)

Targeting Tau to Treat Clinical Features of Huntington's Disease
por: Masnata, Maria, et al.
Publicado: (2020)

Toll-Like Receptor Expression in the Blood and Brain of Patients and a Mouse Model of Parkinson’s Disease
por: Drouin-Ouellet, Janelle, et al.
Publicado: (2015)

The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration
por: Drouin-Ouellet, Janelle, et al.
Publicado: (2011)

Spectrum of Tau Pathologies in Huntington’s disease
por: Baskota, Swikrity Upadhyay, et al.
Publicado: (2019)

Distinct subcellular autophagy impairments in induced neurons from patients with Huntington's disease
por: Pircs, Karolina, et al.
Publicado: (2021)

Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson’s disease
por: St-Amour, Isabelle, et al.
Publicado: (2012)

Age-related pathological impairments in directly reprogrammed dopaminergic neurons derived from patients with idiopathic Parkinson’s disease
por: Drouin-Ouellet, Janelle, et al.
Publicado: (2022)

Direct Neuronal Reprogramming for Disease Modeling Studies Using Patient-Derived Neurons: What Have We Learned?
por: Drouin-Ouellet, Janelle, et al.
Publicado: (2017)

Simple Generation of a High Yield Culture of Induced Neurons from Human Adult Skin Fibroblasts
por: Shrigley, Shelby, et al.
Publicado: (2018)

Dermal fibroblasts from patients with Parkinson’s disease have normal GCase activity and autophagy compared to patients with PD and GBA mutations
por: Collins, Lucy M, et al.
Publicado: (2018)

An in vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicity
por: Cisbani, G, et al.
Publicado: (2012)

A quantitative model of cellular decision making in direct neuronal reprogramming
por: Merlevede, Adriaan, et al.
Publicado: (2021)

Reprogramming Human Adult Fibroblasts into GABAergic Interneurons
por: Bruzelius, Andreas, et al.
Publicado: (2021)

Editorial: Tau Pathology in Neurological Disorders
por: Do Carmo, Sonia, et al.
Publicado: (2021)

Platelet abnormalities in Huntington’s disease
por: Denis, Hélèna L, et al.
Publicado: (2019)

REST suppression mediates neural conversion of adult human fibroblasts via microRNA‐dependent and ‐independent pathways
por: Drouin‐Ouellet, Janelle, et al.
Publicado: (2017)

Cell‐based therapy for Parkinson's disease: A journey through decades toward the light side of the Force
por: Parmar, Malin, et al.
Publicado: (2018)

Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington’s disease
por: Di Pardo, Alba, et al.
Publicado: (2017)

Tau: A Common Denominator and Therapeutic Target for Neurodegenerative Disorders
por: Maxan, Alexander, et al.
Publicado: (2018)

Microglial physiological properties and interactions with synapses are altered at presymptomatic stages in a mouse model of Huntington’s disease pathology
por: Savage, Julie C., et al.
Publicado: (2020)

Author Correction: Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington’s disease
por: Di Pardo, Alba, et al.
Publicado: (2018)

Parkinson's Disease in a Dish: What Patient Specific-Reprogrammed Somatic Cells Can Tell Us about Parkinson's Disease, If Anything?
por: Drouin-Ouellet, J., et al.
Publicado: (2012)

Outcome of cell suspension allografts in a patient with Huntington's disease
por: Maxan, Alexander, et al.
Publicado: (2018)

Current Understanding of the Glial Response to Disorders of the Aging CNS
por: Barker, Roger A, et al.
Publicado: (2012)

Neurodegenerative disorders: the Glia way forward
por: Barker, Roger A., et al.
Publicado: (2014)

The glial response to intracerebrally delivered therapies for neurodegenerative disorders: is this a critical issue?
por: Cicchetti, Francesca, et al.
Publicado: (2014)

Novel targets for Huntington’s disease: future prospects
por: Mason, Sarah L, et al.
Publicado: (2016)

Neuronal expression of pathological tau accelerates oligodendrocyte progenitor cell differentiation
por: Ossola, Bernardino, et al.
Publicado: (2015)

Implications of Tau Dysregulation in Huntington’s Disease and Potential for New Therapeutics
por: Mees, Isaline, et al.
Publicado: (2023)

The Morphological and Molecular Changes of Brain Cells Exposed to Direct Current Electric Field Stimulation
por: Pelletier, Simon J., et al.
Publicado: (2015)

Skeletal muscle pathology in Huntington's disease
por: Zielonka, Daniel, et al.
Publicado: (2014)

Premanifest Huntington’s disease: Examination of oculomotor abnormalities in clinical practice
por: Winder, Jessica Y., et al.
Publicado: (2018)

Propagation of Tau aggregates
por: Goedert, Michel, et al.
Publicado: (2017)

Correction: Shedding a new light on Huntington’s disease: how blood can both propagate and ameliorate disease pathology
por: Rieux, Marie, et al.
Publicado: (2020)

Tau or neurofilament light—Which is the more suitable biomarker for Huntington’s disease?
por: Niemelä, Valter, et al.
Publicado: (2017)

Altered Levels and Isoforms of Tau and Nuclear Membrane Invaginations in Huntington’s Disease
por: Fernández-Nogales, Marta, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vtfl93fgmd4igq3cpfebth8h7t